PYC Therapeutics (PYC) Q1 2026 earnings summary

Executive summary

• Recent financing has strengthened the balance sheet, enabling advancement of four pipeline assets, including three in human trials and one in pre-clinical stage, with a focus on disease-modifying RNA therapeutics for severe genetic diseases with high unmet need.

• Tier 1 specialist investors have joined, aligning incentives and providing strategic industry connections.

• Pipeline includes four clinical-stage assets aiming for human efficacy data between 2025 and 2027, addressing severe unmet medical needs.

• Achieved key clinical milestones in PKD, RP11, and ADOA, and progressed PMS into IND-enabling studies.

Financial highlights

• Recent capital raise results in a cash balance exceeding $750 million, ensuring operational funding through 2030 and supporting late-stage clinical development.

• Strong shareholder register with substantial new investment, including AUD 333.3 million worth of stock allocated to new investors at the same price as the entitlement offer.

• Ended Q3 2025 with $135 million in cash and cash equivalents, with an additional $20 million R&D rebate expected in Q1 2026.

• Net cash used in operating activities for the quarter was $17.4 million, primarily for R&D.

Outlook and guidance

• All four pipeline assets are expected to deliver human safety and efficacy data within the next 24 months, with key milestones mapped through 2030.

• Human safety and efficacy data for RP11 expected in 2025, PKD and ADOA in 2026, and PMS in 2027.

• The PKD program is advancing to repeat dose studies in Q2, with key biomarker and anatomical endpoints ahead.

• Phelan-McDermid syndrome program delayed by 12 months due to requirements for juvenile toxicology studies, targeting IND submission in Q1 next year.

• Ophthalmology programs (RP11 and ADOA) are awaiting long-term efficacy data and regulatory alignment before phase III initiation.